UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii143

2018

Volltextzugriff (PDF)

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

Annals of oncology, 2018-10, Vol.29, p.viii542-viii542

2018

Volltextzugriff (PDF)

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii541-viii542

2018

Volltextzugriff (PDF)

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii732-viii732

2018

Volltextzugriff (PDF)

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies

Annals of oncology, 2016-10, Vol.27, p.vi360-vi360

2016

Volltextzugriff (PDF)

1497PJNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer

Annals of oncology, 2016-10, Vol.27, p.vi582-vi582

2016

Volltextzugriff (PDF)

1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

LBA40Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

436PPreliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

112OCirculating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

Annals of oncology, 2016-10, Vol.27, p.vi372-vi372

2016

Volltextzugriff (PDF)

A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7082-7082

2011

Volltextzugriff (PDF)

Front-line topotecan (T) with or without whole-brain radiation (WBRT) followed by alternating T and platinum/etoposide (PE) for patients (Pts) with small cell lung cancer (SCLC) and brain metastases (mets)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e18100-e18100

2010

Volltextzugriff (PDF)

A phase II study of celecoxib (C) with irinotecan (I), 5-fluorouracil (F), and leucovorin (L) in patients (pts) with advanced or metastatic colorectal cancer (CRC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3588-3588

2006

Volltextzugriff (PDF)

What sanitation means to the processor

Food industries, 1946-01, Vol.18, p.94

SANBORN, R E

1946

Volltextzugriff (PDF)

Solving personnel problems in a seasonal industry

Food Industries, 1931-10, Vol.3, p.453-454

Sanborn, R E

1931

Volltextzugriff (PDF)

Structural insights into µ-opioid receptor activation

Nature (London), 2015-08, Vol.524 (7565), p.315-321

2015

Volltextzugriff (PDF)

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Clinical cancer research, 2018-06, Vol.24 (12), p.2771-2779

2018

Volltextzugriff (PDF)

A new type of solar-system material recovered from Ordovician marine limestone

Nature communications, 2016-06, Vol.7 (1), p.ncomms11851-ncomms11851, Article ncomms11851

2016

Volltextzugriff (PDF)

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.1901-1911

2019

Volltextzugriff (PDF)

Integrated intracellular organization and its variations in human iPS cells

Nature (London), 2023-01, Vol.613 (7943), p.345-354

2023

Volltextzugriff (PDF)

1 – 25 von 305

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(261)
Mit Volltextzugriff
(230)

Publikationsform

Sprache

Englisch
(304)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies

1497PJNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer

1496PIntracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

LBA40Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

436PPreliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

112OCirculating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group

Front-line topotecan (T) with or without whole-brain radiation (WBRT) followed by alternating T and platinum/etoposide (PE) for patients (Pts) with small cell lung cancer (SCLC) and brain metastases (mets)

A phase II study of celecoxib (C) with irinotecan (I), 5-fluorouracil (F), and leucovorin (L) in patients (pts) with advanced or metastatic colorectal cancer (CRC)

What sanitation means to the processor

Solving personnel problems in a seasonal industry

Structural insights into µ-opioid receptor activation

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

The Energetics and Physiological Impact of Cohesin Extrusion

A new type of solar-system material recovered from Ordovician marine limestone

Transcription Restores DNA Repair to Heterochromatin, Determining Regional Mutation Rates in Cancer Genomes

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

Integrated intracellular organization and its variations in human iPS cells

Suchergebnisse filtern